You are here

  • Home
  • Archive
  • Volume 13, Issue 10
  • Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial

Citation Tools

Article menu
Epidemiology
Protocol
Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Djimde M, Tshiongo JK, Muhindo HM, et al
Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial
BMJ Open 2023;13:e065295. doi: 10.1136/bmjopen-2022-065295